what should i take with retatrutide to Know About Weight-Loss Drug| RealSelf News What Not to Take With

This is your fact-finding mission

The DAPA-HF trial demonstrated a 30% reduction in heart failure hospitalizations, while the DAPA-CKD trial showed a 39% reduction in chronic kidney disease progression

The cycling structure reflects the available pharmacology of the peptide and the broader principle that no peptide protocol should be open-ended

Endocrine 75(3):663671 Ma C, Ding H, Deng Y, Liu H, Xiong X, Yang Y (2021) Irisin: a new code uncover the relationship of skeletal muscle and cardiovascular health during exercise

avoid diuretics | | Oral bisphosphonates (alendronate) | Gastric emptying delay may reduce already-low bioavailability | Efficacy loss possible | Minor | Take bisphosphonate on empty stomach 30 min before triple agonist | Prescribing Framework for Triple Agonists No FDA-approved labeling for retatrutide existed as of July 2025, but phase 2 and phase 3 trial protocols establish a de facto dosing framework that clinicians in early-access or clinical-trial settings follow

These rates are comparable to other GLP-1 agonist side effects but amplified by the triple mechanism